Aparna Raj Parikh, MD, MS

Aparna Parikh, MD, and the Oncology Brothers have a comprehensive discussion on treatment decision-making practices for patients with colon cancer, highlighting considerations such as high microsatellite instability and refractory disease.

Medical oncologists give an overview of the treatment algorithm for metastatic colon cancer.

The Oncology Brothers and Aparna Parikh, MD, review the treatment algorithm for patients with stage III colon cancer.

Dr Parikh provides insights on the role of circulating tumor DNA in the treatment of patients with colon cancer.

Aparna Parikh, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment of patients with localized colon cancer, primarily focusing on stage II disease.

The expert panel concludes its discussion with a focus on the future of MRD testing in colorectal cancer, highlighting the treatment landscape’s current strengths and challenges.

Focusing on the BESPOKE CRC study, John H. Strickler, MD, reviews recent updates presented at ASGO GI 2024 and discusses subset analyses from the trial.

An overview of the rationale and study design of the INTERCEPT study in patients with colorectal cancer, with a focus on the early key findings.

Arvind N. Dasari, MD, MS, presents the third patient profile of the discussion, a 62-year-old woman with colon cancer, highlighting the role of MRD testing in guiding treatment decisions in the surveillance setting.

Stacey Cohen, MD, reviews the initial results from the phase 2 COBRA study focused on ctDNA as a predictive biomarker in adjuvant chemotherapy for patients with stage II colon cancer.

Arvind N. Dasari, MD, MS, gives an overview of the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA clinical trial.

Experts on colorectal cancer provide comprehensive insights on the GALAXY study, highlighting key updates that were presented at ASCO GI 2024.

Aparna Parikh, MD, reviews the DYNAMIC trial, which is focused on ctDNA-guided adjuvant therapy in early-stage colorectal cancer.

Stacey Cohen, MD, presents the case of a 39-year-old woman with high-risk stage II colorectal cancer, highlighting how ctDNA helped inform treatment selection.

The expert panel provides a comprehensive overview of the COSMOS-CRC-03 study and touch on the importance of also looking at real-world data.

An overview of prospective trial data surrounding MRD testing in early-stage CRC and the impact of these findings on the overall treatment landscape.

Michael Foote, MD, presents the case of a 50-year-old man with stage III colorectal cancer, highlighting the role of MRD testing in patient monitoring and treatment management.

GI medical oncologists discuss MRD testing practices in colorectal cancer and provide insights on challenges associated with testing.

Arvind N. Dasari, MD, MS, provides clinical insights on MRD testing modalities, highlighting factors that inform the decision on which platform to use in practice.

A panel of medical oncologists introduce themselves and provide an overview of circulating tumor DNA (ctDNA) and how it relates to MRD (minimal residual disease) testing in colorectal cancer (CRC).

The expert panel offers closing thoughts on MRD assessment and how ctDNA has been incorporated into clinical practice in the treatment of colorectal cancer.

Specialists on colorectal cancer discuss the effect of MRD on monitoring strategies and adjuvant therapy decisions for patients with colorectal cancer.

An overview colorectal cancer clinical trials studying early intervention based on MRD positivity.

Aparna Parikh, MD, MS, talks about the MD Anderson INTERCEPT program, which is studying the relationship between ctDNA and recurrence in colorectal cancer.

Daniel H. Ahn, DO, discusses the CIRCULATE-Japan trial, which is studying how ctDNA can be used to guide adjuvant therapy in colorectal cancer.

The panel compares cfDNA with ctDNA for assessing MRD, and outlines when ctDNA testing is ordered and how it’s collected.

Joleen Hubbard, MD, compares CEA with ctDNA for monitoring patients with colorectal cancer.

Medical oncologists who specialize in gastrointestinal cancers offer clinical insights on monitoring patients following treatment with adjuvant chemotherapy.

A comprehensive discussion on treatment decision-making for patients with colorectal cancer following the IDEA collaboration analysis.

The expert panel discusses how MRD positivity affects treatment decisions for patients with colorectal cancer.